NeoGenomics announced preliminary results for the third quarter of 2026, expecting total revenue of approximately $209 million. The company also unveiled a leadership succession plan, with current COO Warren Stone set to succeed Tony Zook as CEO in January 2027. Management indicated that strong quarterly performance, particularly within the sequencing business, will likely drive an upward revision to full-year revenue guidance when final results are reported.
Key Highlights
- Preliminary third quarter revenue reached $209 million, reflecting continued demand for oncology diagnostic solutions.
- Next-generation sequencing (NGS) revenue grew approximately 28% year-over-year, representing a significant growth driver for the clinical services segment.
- The company expects to increase its full-year 2026 total revenue guidance at the midpoint, though it currently reiterated its previous guidance and Adjusted EBITDA targets.
- Chief Executive Officer Tony Zook will transition to the role of Executive Chairman on January 4, 2027, with Warren Stone appointed to the CEO role and the Board of Directors.